

1 TITLE: Examining inappropriate medication in UK  
2 primary care for type 2 diabetes patients with  
3 polypharmacy.

4

5 **AUTHORS NAMES AND AFFILIATIONS:**

6 Maria Luisa Faquetti<sup>1</sup>, Géraldine Frey<sup>1</sup>, Dominik Stämpfli<sup>1,2</sup>, Stefan Weiler<sup>1</sup>, Andrea M. Burden<sup>1,3</sup>

7

8 <sup>1</sup>Pharmacoepidemiology group, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.

9 <sup>2</sup>Hospital Pharmacy, Kantonsspital Baden, Baden, Switzerland.

10 <sup>3</sup>Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.

11

12 **AUTHORS INFORMATION:**

13 Maria Luisa Faquetti

14 ORCID ID: 0000-0002-5990-3322

15 E-mail address: maria.faquetti@pharma.ethz.ch

16

17 Géraldine Frey

18 E-mail address: freyge@student.ethz.ch

19

20 Dominik Stämpfli

21 ORCID ID: 0000-0001-5293-134X

22 E-mail address: dominik.staempfli@pharma.ethz.ch

23

24 Stefan Weiler

25 ORCID ID: 0000-0003-1087-7597

26 E-mail address: stefan.weiler@pharma.ethz.ch

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 **CORRESPONDENCE TO:**

28 Prof. Dr Andrea M. Burden

29 Institute for Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich,

30 HCI H 407 Vladimir-Prelog-Weg 4, 8093 Zürich, Switzerland.

31 ORCID ID: 0000-0001-7082-8530

32 E-mail address: [andrea.burden@pharma.ethz.ch](mailto:andrea.burden@pharma.ethz.ch)

## 33 Abstract:

34 **Aims:** To estimate the prevalence of potentially inappropriate prescriptions (PIPs) in patients starting  
35 their first non-insulin antidiabetic treatment (NIAD) using two explicit process measures of the  
36 appropriateness of prescribing in UK primary care, stratified by age and polypharmacy status.

37 **Methods:** A descriptive cohort study between 2016 and 2019 was conducted to assess PIPs in patients  
38 aged  $\geq 45$  years at the start of their first NIAD, stratified by age and polypharmacy status. The American  
39 Geriatrics Society (AGS) Beers criteria 2015 was used for older ( $\geq 65$  years) and the Prescribing  
40 Optimally in Middle-age People's Treatments (PROMPT) criteria for middle-aged (45-64 years)  
41 patients. Prevalence of overall PIPs and individual PIPs criteria was reported using the IQVIA Medical  
42 Research Data incorporating THIN, a Cegedim Database of anonymised electronic health records in  
43 the UK.

44 **Results:** Among 28,604 patients initiating NIADs, 18,494 (64.7%) received polypharmacy. In older and  
45 middle-aged patients with polypharmacy, 39.6% and 22.7%, respectively, received  $\geq 1$  PIPs. At the  
46 individual PIPs level, long-term PPI use and strong opioid without laxatives were the most frequent  
47 PIPs among older and middle-aged patients with polypharmacy (11.1% and 4.1%, respectively).

48 **Conclusions:** This study revealed that patients starting NIAD treatment receiving polypharmacy have  
49 the potential for pharmacotherapy optimisation.

50

## 51 Keywords:

52 Inappropriate prescribing; polypharmacy; Diabetes mellitus type 2; Potentially inappropriate  
53 medication list; Primary healthcare; Inappropriate medication.

54

## 55 Funding information:

56 The authors received no external funding for this work.

57

## 58 Data availability statement:

59 The data that support the findings of this study are available from IQVIA Medical  
60 Research Data (IMRD) incorporating THIN, a Cegedim database of anonymised electronic health  
61 records in the UK. Restrictions apply to the availability of these data, which were used under license  
62 for this study. For further information on how to access the data, contact IQVIA  
63 at [IMRDEnquiries@iqvia.com](mailto:IMRDEnquiries@iqvia.com).

64 Conflict of interest:

65 The authors declare that they have no known competing financial interests or personal relationships  
66 that could have appeared to influence the work reported in this paper.

67

## 68 1 Introduction

69 Type 2 diabetes mellitus (T2DM) is a complex chronic metabolic disorder affecting approximately 537  
70 million adults worldwide, with nearly 90% having T2DM.[1] T2DM is characterised by insulin resistance  
71 and progressive decline of insulin production by pancreatic  $\beta$ -cell dysfunction.[2] While T2DM  
72 incidence rises with age, rates of T2DM onset in younger patients are increasing, leading to new public  
73 health challenges.[3] Pharmacological management of individuals with T2DM is often complex,  
74 especially when concomitant chronic conditions and diabetes complications are present, which may  
75 result in the use of multiple medications, also known as polypharmacy.[4] Moreover, patients with  
76 multimorbidity may attend multiple physicians, leading to fragmented, uncoordinated medication  
77 prescriptions.

78 Polypharmacy, generally defined as the concomitant use of five or more drugs, may be required to  
79 manage multiple coexisting conditions, presenting a risk of both undertreatment and  
80 overtreatment.[5] Although the correct combination of drugs in patients with T2DM can improve their  
81 health status and quality of life, polypharmacy increases the likelihood of potentially inappropriate  
82 prescriptions (PIPs), which can thereby increase the risk of experiencing an adverse drug event (ADE),  
83 drug-drug interaction (DDI), or drug-disease interaction.[6,7]

84 Furthermore, patients and society expect the benefits of medicines to outweigh their risks. However,  
85 patients are not equally receptive to beneficial effects and not equally susceptible to ADE. Factors  
86 such as comorbidities, concurrent prescribing of drugs with potential for interaction, and  
87 inappropriate prescribing can all contribute to this variability.[8] Therefore, it is crucial to ensure that  
88 medications are prescribed appropriately, considering individual patients' situations, to minimise the  
89 risks and maximise the benefits.

90 The appropriateness of prescribing medication can be assessed by using implicit process measures  
91 (i.e., judgement based, focused on individual patients) or by using explicit process measures (i.e.,  
92 criterion-based). Among the most commonly used explicit process measures are the American  
93 Geriatrics Society (AGS) Beers criteria[9] and the Prescribing Optimally in Middle-age People's  
94 Treatments (PROMPT),[10] which were tailored to identify drugs to be avoided in older and middle-  
95 aged adults, respectively, independent of a diagnosis or in the context of a disease. While previous  
96 studies, predominantly among the elderly, have identified that the prevalence of PIPs is between 20%  
97 and 79%, depending on the population and setting,[11–16] less is known among patients with T2DM,  
98 particularly non-elderly.

99 The study by Oktora and colleagues revealing that the prevalence of  $\geq 1$  PIP among patients aged 45+  
100 years with T2DM and polypharmacy using Beers and PROMPT ranged from 24.9% to 39.0% was limited

101 to information on drug prescriptions, which hindered implementation of most of the criteria.[14]  
102 Thus, no large population-based study encompassing clinical information has applied these measures  
103 to identify drugs to be avoided in the context of diseases or under specific situations in patients with  
104 T2DM.

105 The overall aim of this study was to estimate the prevalence of PIPs in middle-aged and older adults  
106 starting their first non-insulin antidiabetic treatment (NIAD) using two explicit process measures of  
107 appropriateness of prescribing medication in a primary care database from the UK, stratified by age  
108 and polypharmacy status. This study aimed to identify if pharmacotherapy could be optimised and,  
109 ultimately, to provide clinical insights into the management of patients with T2DM receiving multiple  
110 medications in primary care.

111

## 112 2 Materials and Methods

113

### 114 2.1 Study design and data source

115 We conducted a descriptive cohort study using data from primary care practices in the UK between  
116 2016 and 2019 to assess PIPs in patients at the start of their first NIAD, stratified by age and  
117 polypharmacy status. The data were obtained from IQVIA Medical Research Data (IMRD;  
118 incorporating data from THIN, A Cegedim Database of anonymised electronic health records in the  
119 UK). IMRD is an extensive database containing longitudinal non-identified electronic medical records  
120 collected from general practices in the UK from over 18 million patients, of which approximately 2.9  
121 million are currently active. IMRD has been shown to be representative of the UK and valid in terms  
122 of age and sex comparisons and a wide range of diseases.[17] Demographic information, clinical  
123 outcomes and diagnosis, lab tests (e.g., estimated glomerular filtration rate [eGFR] and haemoglobin  
124 A1c [HbA1c]), drug prescriptions, specialist referrals, and other information (e.g., smoking status,  
125 pregnancy, and death) are recorded in the database by general practitioners (GPs). Medications are  
126 recorded using the British National Formulary (BNF) classification and were manually mapped to their  
127 corresponding International Anatomical Therapeutic Classification (ATC) code. As the IMRD consists  
128 of primary care records, medication dispensed during hospitalisation, nor those prescribed by  
129 specialists, are included in the database. All diagnoses are recorded using Read codes.[17]

130

## 131 2.2 Study population

132 The study population consisted of all adults aged  $\geq 45$  years who received a first-ever NIAD prescription  
133 between January 2016 and December 2019. Cohort entry (index date) was defined as the date of the  
134 first-ever NIAD prescription. Patients included were classified by age at index date as older adults ( $\geq 65$   
135 years) or middle-aged adults (45-64 years). Patients were allowed to have multiple co-prescribed  
136 NIADs at the index date. All patients were required to have  $\geq 1$  year of database history and at least  
137 one GP visit before the index date. We only considered patients registered with a practice with a valid  
138 up-to-standard date, who had valid entries (i.e., a valid patient flag), and with a first NIAD prescription  
139 with a valid flag in the database. Patients diagnosed with gestational diabetes, polycystic ovary  
140 syndrome, cancer (except by non-melanoma skin cancers), or insulin therapy previous to, or at, the  
141 index date were excluded. Additionally, patients in palliative care or at end-of-life were excluded. All  
142 comorbidity or palliative/end-of-life care patients were identified using Read codes.

143

## 144 2.3 Polypharmacy definition

145 We leveraged an existing cohort of patients with T2DM and polypharmacy, which is described in detail  
146 elsewhere.[18] In brief, polypharmacy was defined as the prescription of  $\geq 5$  different drug compounds  
147 on or within 90 days before the index date. We identified patients with polypharmacy at the start of  
148 NIAD therapy and only considered drugs and diagnoses (i.e., history of comorbidities and medical  
149 conditions in the Beers or PROMPT criteria for assessing PIP) with a valid flag in the database.  
150 Additional details on the selection of drugs for the polypharmacy analysis are available in  
151 Supplementary Information.

152

## 153 2.4 Potentially inappropriate prescriptions (PIPs)

154 We used the AGS Beers criteria for assessment of PIPs in patients aged  $\geq 65$  years,[9] and the PROMPT  
155 criteria for patients aged 45 to 64 years, at the start of the first NIAD.[10] The Beers criteria includes  
156 lists of potentially inappropriate drugs that should be avoided in patients aged  $\geq 65$  years as a whole  
157 or those with certain medication conditions or at an increased risk of an ADE or DDI.[9] The 2015  
158 version was the latest published version for the years 2016-2019. The PROMPT criteria are used to  
159 optimise medication prescribing practices for middle-aged adults (i.e., 45-64 years old).[10] It includes  
160 recommendations relevant to this age group considering age-related factors, such as differences in  
161 the prevalence of diseases and polypharmacy.

162 While Beers list encompasses 92 criteria, PROMPT has 22 criteria. For the assessment of PIPs, we  
163 included only those criteria that can be fully or partially applied in a primary care database, without  
164 information on drugs prescribed during hospital stay or in secondary care. We excluded 17 criteria  
165 from Beers (i) because of unavailability of data (e.g., severity of disease, medication prescribed during  
166 hospital stay, or dose reduction information in patients with reduced kidney function), or (ii) they were  
167 ruled out by study design (i.e., due to exclusion criteria), resulting in 75 indicators from Beers and 22  
168 from PROMPT included in the analysis. Nevertheless, the availability of clinical and prescription  
169 information allowed a larger number of Beers and PROMPT criteria to be applied than in previous  
170 studies.[14,19] Moreover, a multidisciplinary team collaborated to align the applicability of each  
171 criterion using primary care data, aiming to find consensus through the lists and achieve optimal  
172 results in a consistently manner. To accommodate differences between the US and UK drug  
173 availability, we adapted the Beers criteria by including drugs from the BNF previously published.[20]  
174 As PROMPT was tailored to the UK and the Republic of Ireland, no adaptation regarding the drug list  
175 was needed.

176 The list of criteria used, their recommendation, rationale, applicability using primary care data (i.e.,  
177 fully applied or partially applied), limitation, and an extensive description used in each criterium to  
178 assess PIPs according to Beers and PROMPT are listed in the Supplementary Table S1 and  
179 Supplementary Table S2, respectively. Additionally, information on ATC codes considered for the  
180 identification of the corresponding drugs and Read codes considered for identification of the  
181 corresponding diagnosis in each criterion are listed in Supplementary Table S3 for Beers and  
182 Supplementary Table S4 for PROMPT criteria. All codes were manually reviewed and confirmed by a  
183 medical doctor and clinical pharmacist.

184 Patients were categorised into those who received a PIP criteria drug, drug combination, or drug-  
185 disease combination. Criteria which specified a particular dosage not to exceed, such as prescription  
186 of proton pump inhibitors (PPIs) above recommended maintenance dosages for >8 weeks (PROMPT  
187 criteria 22), were assessed by calculating the daily dose using the strength, quantity prescribed, and  
188 the dose per day or duration for each prescription in the period of assessment.

189 Whenever dosage information was not available in the data set for drugs of which judgment of  
190 appropriate use was dependant on prescribed dose or duration, the cumulative dose (CD) was  
191 calculated per drug compound in the database using the defined daily dose (DDD) by the ATC index  
192 whenever provided (available at [https://www.whooc.no/atc\\_ddd\\_index/](https://www.whooc.no/atc_ddd_index/)). This index represents an  
193 average maintenance dose per day for a drug used for its main indication in adults, and thus allows  
194 for comparisons of drug consumption at an international level. Moreover, the ATC index is freely  
195 available worldwide. Whenever the ATC index was not available, we adopted the (minimal) daily dose



196 recommended by the BNF formulary, as specified in the 'PIPs definition' in Supplementary Table S1  
197 and Supplementary Table S2. Finally, for multiple prescriptions with only one record having  
198 information on dosage/frequency, we assumed the same prescription mode for all prescriptions of  
199 the same drug compound for the same patient.

200

## 201 2.5 Statistical analysis

202 We reported patient characteristics at index date, stratified by age groups (40-64 years and 65+) and  
203 polypharmacy status (<5 drugs and 5+), as a mean and standard deviation or median and interquartile  
204 range (IQR) or counts and proportions, as applicable. We identified alcohol use and smoking based  
205 upon the most recent value recorded in the database (i.e., either at or before index date). Body mass  
206 index was calculated using the value closest to the index date. However, as the height of an individual  
207 is not likely to vary significantly during adulthood, the closest value to the index date (before or after)  
208 was considered. We summarised the mean HbA1c and eGFR using the most recently recorded values  
209 up to the previous six months prior to the index date, and a history of comorbidities was assessed if  
210 ever registered in the database before the index date. We reported all patient characteristics among  
211 older and middle-aged adults, stratified by polypharmacy status.

212 We estimated the number of PIPs per patient at the start of the first NIAD treatment in each of the  
213 strata, which was identified as the number of patients with at least one day with any PIPs. Additionally,  
214 for the individual PIPs criteria, prevalence was reported in patients receiving at least one day of the  
215 drug(s) under evaluation of PIPs at or within 90 days to index date. As a sensitivity analysis, for drugs  
216 of which judgment of PIPs was dependent on prescribed dose or duration, the prevalence of PIPs was  
217 reported separately for patients having complete information on dose or duration by dividing the  
218 patient number by the total number of patients with complete information on dose or duration.  
219 Numbers fewer than seven are suppressed according to data use agreement with IMRD. All analyses  
220 were performed using the R software version (4.1.2). The study protocol was approved by the IQVIA  
221 Scientific Research Committee (study reference number: 22SRC047).

222

## 223 3 Results

224 A total of 28,604 patients initiating a NIAD between 2016 and 2019 (Figure 1) were eligible for  
225 inclusion. The demographic characteristics at the index are provided in Table 1, stratified by age and  
226 polypharmacy status. Overall, 18,494 (64.7%) patients had polypharmacy at the index date or within  
227 90 days before the index date and were categorised as having polypharmacy. The prevalence of

228 polypharmacy increased with age (older adults = 77.8%; middle-aged adults = 55.2%), and  
229 sulfonylureas (SU), dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter  
230 (SGLT-2) inhibitors were prescribed more frequently (alone or in combination with metformin) in  
231 patients receiving polypharmacy compared to no polypharmacy regardless of age.

232 Among older patients without polypharmacy, 6.5% received  $\geq 1$  PIP with a maximum of four PIPs per  
233 patient, while 39.6% of those with polypharmacy had  $\geq 1$  PIP with a maximum of 10 PIPs per patient  
234 (Table 2). Similarly, the prevalence of PIPs was higher among middle-aged adults with polypharmacy  
235 than in those without. Among middle-aged adults without polypharmacy, few PIPs were identified,  
236 with 98.5% of patients having no PIPs, while 22.7% of those with polypharmacy had  $\geq 1$  PIP with a  
237 maximum of four PIPs per patient (Table 2).

238 Table 3 provides the prevalence of PIPs among older adults according to the Beers criteria. The most  
239 frequently occurring PIP was the use of PPIs for  $>8$  weeks unless for high-risk patients (criteria 33 [n =  
240 1,034, 11.1%]), followed by the use of high anticholinergic antidepressants monotherapy or in  
241 combination to other drugs for management of depression (criteria 16 [n=951, 10.2%]), the use of  
242 antipsychotics, benzodiazepines (BZD), non-BZD, BDZ receptor agonist hypnotics, tricyclic  
243 antidepressants (TCA) and selective serotonin reuptake inhibitors (SSRI) in patients with a history of  
244 falls or fractures (criteria 3 [n=911, 9.8%]), and the use of peripheral alpha-1 blockers in patients with  
245 hypertension (criteria 2 [n=495, 5.3%]). Among patients having no polypharmacy, the most frequent  
246 PIPs were PPI use  $>8$  weeks unless for high-risk patients, erosive esophagitis, Barrett's esophagitis,  
247 pathological hypersecretory condition, or demonstrated need for maintenance treatment (criteria 33  
248 [n=46, 1.7%]) and the use of antidepressants monotherapy or in combination to other drugs for  
249 management of depression (criteria 16 [n=31, 1.2%]). The sensitivity analysis identifying the  
250 prevalence of individual PIPs among patients having complete information on dose or duration is  
251 shown in Table 3.

252 The prevalence of individual PIPs in middle-aged adults at the start of the first NIAD treatment is  
253 provided in Table 4. The highest prevalence in middle-aged patients with polypharmacy was observed  
254 for strong opioids without co-prescription of laxatives (criteria 17 [n=381, 4.1%]); followed by the  
255 combination of non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin (acetylsalicylic  
256 acid) or SSRI without adequate gastrointestinal protection (criteria 21 [n=361, 3.9%]), long-term use  
257 of BZD (criteria 14 [n=293, 3.2%]), and PPI use above maintenance dosages for  $>8$  weeks (criteria 2  
258 [n=269, 2.9%]). In contrast, in patients having no polypharmacy, the highest prevalence was observed  
259 for first-generation anti-histamines as first-line treatment  $>7$  days (criteria 8 [n= 14, 0.2%]) and for PPI  
260 above maintenance dose for  $>8$  weeks (criteria 2 [n=13, 0.2%]). The sensitivity analysis identifying the

261 prevalence of individual PIPs among patients having complete information on dose or duration is  
262 shown in Table 4.

## 263 4 Discussion

264 This is the first study to apply the Beers and the PROMPT and list to a large population-based primary  
265 care database to evaluate the prevalence of PIPs among both older and middle-aged adults initiating  
266 therapy for T2DM with and without polypharmacy. The prevalence of PIPs was overall higher in  
267 patients receiving polypharmacy compared to no polypharmacy. While the prevalence of PIPs was  
268 higher among older patients with polypharmacy (39.6%), we found that 22.7% of middle-aged patients  
269 with polypharmacy received  $\geq 1$  PIPs. At the individual PIP level, long-term use of PPIs and strong  
270 opioids without laxatives were the most frequently identified PIPs among older patients (criteria 33)  
271 and middle-aged patients (criteria 17), respectively, with polypharmacy (11.1% and 4.1%,  
272 respectively). The results of this study highlight the frequency of PIPs among patients with T2DM and  
273 the subsequent importance of medication reviews to avoid harmful adverse events due to PIPs.

274 While this is the first study to apply the Beers and PROMPT criteria to patients initiating their first  
275 NIAD treatment, our results align with the existing literature.[13,14,16,21–24] The only study to date,  
276 that has applied both Beers and PROMPT in patients with T2DM receiving polypharmacy to assess  
277 PIPs, observed higher PIPs prevalence in middle-aged patients (36.9% to 39.0%) than in older patients  
278 (24.9% to 28.0%).[14] Limitations included the absence of clinical information, and, therefore, fewer  
279 criteria were assessed. The latter is particularly important for the criteria related to medication with  
280 multiple indications. While our study was also limited by missing information, we could address more  
281 criteria due to the availability of clinical parameters and synchronization of data and criteria list  
282 through a multidisciplinary team, including a clinical pharmacologist and a clinical pharmacist. For  
283 example, in PROMPT criteria number 13, the lack of information on depression diagnosis implicates  
284 the overestimation of PIPs, particularly because TCA is used within different indications. While we  
285 acknowledge the diagnosis codes for depression are subject to misclassification and are an  
286 underestimation of true prevalence, we were able to combine our prescribing data with previous  
287 diagnosis and clinical patient records to overcome this limitation.

288 Another study using Beers criteria to assess PIPs in elderly with T2DM and polypharmacy identified  
289 that the prevalence of PIPs was 54.5%.[13] While this is substantially higher than the 39.6% found in  
290 our study, we expect the difference is largely due to differences in the study population. The study by  
291 Formiga et al. included patients age 75+ who were admitted to the hospital, while we included all  
292 older adults initiating a NIAD in general practice with a mean age of 73.7 years.[13] Thus, we expect

293 that our results more likely reflect the prevalence of PIPs in the general population of older adults  
294 with diabetes.

295 As the number of studies assessing the Beers and PROMPT criteria in patients with T2DM is limited,  
296 we also note that our results are comparable to the reported prevalence of PIPs in the general  
297 population. Studies applying Beers and PROMPT showed PIPs prevalence ranging from 34.2% to 64.8%  
298 in older adults,[16,19,23,24] and 21.1% to 46.2% in middle-aged adults.[19,21,22] Nonetheless, it is  
299 challenging to draw an accurate one-to-one comparison with most studies, as very often, only part of  
300 the criteria was applied due to limitations on the dataset. Among the studies applying the Beers  
301 criteria, most observational studies implemented a subset of the criteria list.[25] Nevertheless, one  
302 study that implemented the entire list of criteria used administrative claims data from the USA and  
303 included patients 65+, with no stratification between polypharmacy status. The study found the  
304 prevalence of PIPs ranged between 34.2% to 37.6%. As the study did not stratify by polypharmacy  
305 status, it is difficult to directly compare our results. Overall, 3,682 patients (173 without polypharmacy  
306 and 3,682 with polypharmacy) had at least one PIP, which corresponds to a PIP prevalence of 32.3%  
307 among our older adults. While this is marginally lower, than the study by Jirón et al., the marginal  
308 disparities between these estimates may be due to differences between US and UK clinical settings  
309 and data sources used in each study.

310 At the individual PIP level in older adults, the long-term use of PPIs is of particular concern as it may  
311 increase the risk of adverse drug reactions, such as chronic kidney disease, particularly in high  
312 doses,[26] and B12 deficiency.[27] Studies in primary care and emergency settings indicate that PPIs  
313 are frequently prescribed for inappropriate indications or for indications where their use provides  
314 little to no benefit.[28] Moreover, patients may stay long-term on PPIs, often indefinitely, even  
315 without a clear clinical indication.[29,30] Therefore, our findings indicate the need for carefully  
316 reviewing indications of PPIs to minimise the risk of long-term PPI-related adverse outcomes in older  
317 patients with diabetes, particularly in those receiving polypharmacy.

318 The use of high anticholinergic antidepressants (criteria 16 [10.2%]), and SSRIs, BZD, non-BZD  
319 hypnotics, and TCA (criteria 45 [9.8%]) in patients with a history of falls and fractures were among the  
320 most frequent PIPs in older adults found this study as well as in previous work.[13,14] Anticholinergic  
321 antidepressants may cause ADR such as dry mouth, blurred vision, constipation, urinary dysfunction,  
322 sedation, orthostatic hypotension, and cognitive impairment, which all reduce the patient's quality of  
323 life, may lead to increased risk of falls, substantial morbidity, and even mortality.[31] Older adults  
324 have a higher sensitivity to anticholinergic effects, with might worsen pre-existing symptoms.[32,33]  
325 Patients with dementia and depression may become more confused due to the anticholinergic side  
326 effects of some antidepressants as well as patients with orthostatic hypotension may collapse and fall.

327 These concerns become particularly important in patients with diabetes complications, such as  
328 neuropathy, retinopathy, and diabetic cardiomyopathy.[34,35] Although anticholinergic  
329 antidepressants are not the first-line pharmacological therapy for treating depression according to the  
330 clinical guidelines in the UK,[36] we found high prevalence of drug prescription in older patients. While  
331 further research on the appropriateness is needed, our results indicate that clinicians do not withhold  
332 from prescribing highly anticholinergic antidepressants to older patients with diabetes and  
333 polypharmacy, despite their potential to cause ADR and the availability of safer alternatives.

334 The use of SSRIs, BZD, non-BZD, and TCA is associated with an increased risk of falls and fractures,[37–  
335 39] a primary concern for elderly adults with T2DM. These drugs are often prescribed to the elderly  
336 for prolonged periods, without the repeat prescription being reviewed.[39,40] BZD have long been  
337 recognised as a contributory factor for falls. Non-BZD hypnotics are considered safer than BZD,  
338 however, they have an increased risk for falls when used in long-term.[38] Notably, in the UK, TCA  
339 drugs such as amitriptyline, prescribed in low doses for longer term, are considered appropriate to  
340 treat neuropathic pain.[41] Thus, although indications cannot be determined from our dataset, the  
341 high prevalence of TCA prescription in patients with T2DM may be, at least partially, for its use in pain  
342 management. Additionally, despite warnings on the clinical guideline for treating depression in the UK  
343 regarding the use of antidepressants in older people with increased risk of falls and fractures,[36] our  
344 study indicates that clinicians do not refrain from prescribing these drugs to older patients with a  
345 history of falls and fractures which are risk factors for new events. This is of particular concern in older  
346 patients with T2DM: besides the risk of falls and fractures increase with age,[42] complications of  
347 diabetes (e.g., neuropathy and vision loss) and NIAD treatment adverse effects (e.g., hypoglycaemia  
348 in patients receiving SU), can further increase this risk.[43]

349 At the individual PIP level in middle-aged adults, this study indicates that opioid-related constipation  
350 may not be adequately prevented by clinicians, despite being a significant concern and burden to  
351 patients.[44] Nonetheless, a possible reason for not adding a laxative drug to opioid treatment could  
352 be that patients already benefit from laxatives as over-the-counter (OTC) drugs, and thus, we may  
353 have missed those patients in the primary care dataset.

354 The combination of NSAIDs and SSRIs or low-dose aspirin without gastroprotection (3.9%) was also  
355 identified to be broadly used in middle-aged adults receiving polypharmacy. While drug combinations  
356 with NSAIDs, such as SSRIs and aspirin,[45–47] are risk factors for upper gastrointestinal bleeding  
357 (UGIB), the risk of outcomes associated with these two combinations is attenuated by concomitant  
358 use of a PPI.[47] Thus, this study indicates the need for clinical improvement and may help clinicians  
359 in tailoring therapy to minimise the risk of UGIB in middle-aged adults with T2DM starting their  
360 antidiabetic treatment.

361 Many of the most frequent PIP criteria in this study relate to the inappropriate duration of medication  
362 use. Although short-term use of medications may confide a different risk-benefit ratio than long-term  
363 use and may not be considered inappropriate in specific conditions, the high prevalence of the most  
364 frequent PIPs found in our study is not compatible with only appropriate drug prescriptions. To  
365 approach that, documenting and communicating the intended treatment duration or planned review  
366 dates in the medical records can provide valuable information to clinicians, facilitating regular review  
367 and discontinuation of inappropriate prescriptions.[48] Moreover, open communication with patients  
368 about prescription duration can also help manage expectations and reduce resistance to changing  
369 medication regimens.

370 While GPs may be less likely to discontinue drug prescriptions from secondary care, they play a critical  
371 role in conciliating prescriptions from different settings as well as evaluating the benefit of continuing  
372 drugs based on a risk-benefit assessment and their patient needs. The lack of evidence and the  
373 challenges in assessing treatment benefits and harms were previously identified as barriers to  
374 appropriate prescribing, particularly in older patients with multiple comorbidities.[48] To address that,  
375 evidence-based guidelines have been developed to support deprescribing of specific drugs, such as  
376 PPIs and BZD, which were among the most prevalent PIPs in this study.[49,50] These guidelines may  
377 offer valuable guidance to optimize medication regimens, enhance patient safety, and improve  
378 outcomes.

379 A key strength of this study is the detailed insights into the prevalence of PIPs in patients with new-onset  
380 T2DM, applying the 2015 AGS Beers criteria adapted to the UK to 65-year-olds and older and the  
381 PROMPT criteria to 45- to 64-year-old patients. The availability of primary care clinical data allowed  
382 for a more thorough assessment of PIPs specifying conditions in patients with diabetes compared to  
383 previous studies.[13,14] The IMRD allowed studying a large number of patients starting a NIAD treatment  
384 who are representative of the UK population. In the UK, GPs are central players managing chronic  
385 diseases, coordinating drug prescriptions that may be initially prescribed in secondary care, and thus  
386 have a favourable position to assess their patients' medications across diseases. The sensitivity  
387 analysis confirmed the robustness of the results, where assumptions were necessary. Another  
388 strength is the availability of a clear and detailed definition of each criterion used in this study, which  
389 can be applied in future studies to assess PIPs using large population-based databases, facilitating  
390 interpretation and comparability between studies.

391 Our study also has some limitations. First, the Beers criteria is an extensively used and validated explicit  
392 process measure developed in the US with the intention of providing a valuable tool for assessing the  
393 quality of prescribing in older adults, regardless of their place of residence and their level of frailty.  
394 Thus, to accommodate the differences between the US and UK drug availability, we adapted the Beers

395 criteria by including drugs from the British National Formulary, as previously published by Ble et al.  
396 We note that while several drugs in the Beers criteria are listed as PIPs, they are not inappropriate in  
397 older adults according to the National Institute for Health Care and Excellence (NICE) clinical guidelines  
398 in the UK (e.g., amitriptyline, clomipramine, desipramine, and nortriptyline are indicated for  
399 management of depression,[36] and nitrofurantoin long-term low dose prophylaxis of recurrent  
400 urinary tract infection[52]), whereas other non-recommended drugs (e.g., theophylline as  
401 monotherapy for asthma and COPD) are omitted. Similarly, the Beers criteria do not consider varying  
402 indications for certain drugs (e.g. amitriptyline for the management of neuropathic pain in the  
403 UK).[53] Thus, while Beers identifies those as PIPs, we acknowledge that this may overestimate  
404 inappropriate use in the UK. On the other hand, our estimation of PIP prevalence using Beers is likely  
405 to be more conservative, as Beers seems to underestimate PIP compared to explicit methods tailored  
406 to the context of Europe, such as Screening Tool of Older Persons' Prescriptions (STOPP) and Screening  
407 Tool to Alert to Right Treatment (START) criteria.[13,54] Moreover, although Beers was not tailored  
408 to the context of Europe prescribing, clinically relevant issues associated with the inappropriate use  
409 of drugs identified using Beers remain relevant in Europe. Finally, Beers was readily adapted to our  
410 dataset compared to the STOPP/START criteria.

411 In addition to the above, we expect that we have likely underestimated medication use, and  
412 subsequently PIPs due to limitations with the IMRD. The IMRD only captures drug prescriptions made  
413 by GPs. Thus, we were not able to identify OTC drugs, such as NSAIDs and laxatives. Additionally, drugs  
414 given during hospitalisation and specialist prescriptions are not captured within the database.

415 Another limitation is that the Beers list was not created for use in observational data, and therefore,  
416 not all of the criteria could be applied due to limitations in our observational data. Failure to apply the  
417 full criteria list may have resulted in lower estimates of the overall PIPs prevalence compared to other  
418 studies, as well as overestimation of individual PIPs whenever it was partially applied. A complete  
419 overview of the limitations associated with each specific criterion are available in Supplementary  
420 Table S1 and Table S2. Similarly, due to missing data on some clinical parameters, not all patients had  
421 complete information. To overcome this limitation, we conducted a sensitivity analysis among only those  
422 patients with complete information, and results remained largely similar.

423 Finally, while the DDD by the ATC index does not necessarily correspond to the recommended daily  
424 dose, we had no access to the indication of drugs due to limitations on our dataset, and thus the  
425 exclusive use of BNF formulary as a source of standard daily dose to estimate CD was not feasible.  
426 Nevertheless, as the ATC index is freely available worldwide and allows for comparisons of drug  
427 consumption at an international level, the use of the DDD ATC index represents a valuable alternative  
428 to estimate CD.

## 429 5 Conclusion

430 This analysis using primary care data revealed opportunities for optimizing pharmacotherapy in  
431 patients newly treated with oral antidiabetics. While the burden of polypharmacy, and thus PIPs,  
432 increases with age, this problem is not exclusive to the elderly. Among patients with polypharmacy,  
433 39.6% of older adults had at  $\geq 1$  PIP, compared to 22.7% of middle-aged adults with  $\geq 1$  PIP.  
434 Antidiabetic therapy carries its own challenges and risks, emphasizing the importance of minimizing  
435 risks associated with existing medications. Given the challenges of avoiding polypharmacy in adults  
436 aged  $\geq 45$  years with diabetes, it is crucial to implement measures that review indications, address  
437 drug interactions, and consider comorbidities, reducing the likelihood of inappropriate prescribing.  
438 Initiating treatment with NIADs in patients with polypharmacy should trigger a comprehensive  
439 medication review to optimize prescribing decisions.

440

## 441 Acknowledgement

442 The authors thank Dr Adrian Martinez de la Torre and all members of the Swiss Data Science Center  
443 (SDSC) for their technical support and Prof Dr Theresa Shireman for the stimulating discussions on this  
444 topic.

445

## 446 Authorship

447 AMB: Conceptualisation; Resources; Supervision; Interpretation of results. MLF: Conceptualisation;  
448 Methodology; Formal analysis; Investigation; Interpretation of results; Writing original draft; GF:  
449 Literature review and implementation of the study. DS: Methodology; Contributed to the design and  
450 implementation of the study; Interpretation of results. SW: Methodology; Contributed to the design  
451 and implementation of the study; Interpretation of results. All authors reviewed and contributed  
452 critically to the manuscript.



## 453 References

- 454 [1] Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes  
455 Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for  
456 2045. *Diabetes Res Clin Pract* 2022;183:109119. <https://doi.org/10.1016/j.diabres.2021.109119>.
- 457 [2] Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *The Lancet* 2017;389:2239–51.  
458 [https://doi.org/10.1016/S0140-6736\(17\)30058-2](https://doi.org/10.1016/S0140-6736(17)30058-2).
- 459 [3] Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents  
460 and young adults. *Lancet Diabetes Endocrinol* 2018;6:69–80. [https://doi.org/10.1016/S2213-](https://doi.org/10.1016/S2213-8587(17)30186-9)  
461 [8587\(17\)30186-9](https://doi.org/10.1016/S2213-8587(17)30186-9).
- 462 [4] Teljeur C, Smith SM, Paul G, Kelly A, O’Dowd T. Multimorbidity in a cohort of patients with  
463 type 2 diabetes. *Eur J Gen Pract* 2013;19:17–22. <https://doi.org/10.3109/13814788.2012.714768>.
- 464 [5] Sinnige J, Braspenning JC, Schellevis FG, Hek K, Stirbu I, Westert GP, et al. Inter-practice  
465 variation in polypharmacy prevalence amongst older patients in primary care. *Pharmacoepidemiol*  
466 *Drug Saf* 2016;25:1033–41. <https://doi.org/10.1002/pds.4016>.
- 467 [6] Molokhia M, Majeed A. Current and future perspectives on the management of  
468 polypharmacy. *BMC Fam Pract* 2017;18. <https://doi.org/10.1186/s12875-017-0642-0>.
- 469 [7] Li S-J, Hwang H-F, Yu W-Y, Lin M-R. Potentially inappropriate medication use, polypharmacy,  
470 and falls among hospitalized patients. *Geriatr Gerontol Int* 2022;22:857–64.  
471 <https://doi.org/10.1111/ggi.14473>.
- 472 [8] Eichler H-G, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging  
473 the efficacy–effectiveness gap: a regulator’s perspective on addressing variability of drug response.  
474 *Nat Rev Drug Discov* 2011;10:495–506. <https://doi.org/10.1038/nrd3501>.
- 475 [9] By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American  
476 Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older  
477 Adults. *J Am Geriatr Soc* 2015;63:2227–46. <https://doi.org/10.1111/jgs.13702>.
- 478 [10] Cooper JA, Ryan C, Smith SM, Wallace E, Bennett K, Cahir C, et al. The development of the  
479 PROMPT (PRescribing Optimally in Middle-aged People’s Treatments) criteria. *BMC Health Serv Res*  
480 2014;14:484. <https://doi.org/10.1186/s12913-014-0484-6>.
- 481 [11] Gallagher P, Lang PO, Cherubini A, Topinková E, Cruz-Jentoft A, Montero Errasquín B, et al.  
482 Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients

- 483 admitted to six European hospitals. *Eur J Clin Pharmacol* 2011;67:1175.  
484 <https://doi.org/10.1007/s00228-011-1061-0>.
- 485 [12] Gallagher P, O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate  
486 Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. *Age*  
487 *Ageing* 2008;37:673–9. <https://doi.org/10.1093/ageing/afn197>.
- 488 [13] Formiga F, Vidal X, Agustí A, Chivite D, Rosón B, Barbé J, et al. Inappropriate prescribing in  
489 elderly people with diabetes admitted to hospital. *Diabet Med* 2016;33:655–62.  
490 <https://doi.org/10.1111/dme.12894>.
- 491 [14] Oktora MP, Alfian SD, Bos HJ, Schuiling-Veninga CCM, Taxis K, Hak E, et al. Trends in  
492 polypharmacy and potentially inappropriate medication (PIM) in older and middle-aged people  
493 treated for diabetes. *Br J Clin Pharmacol* 2021;87:2807–17. <https://doi.org/10.1111/bcp.14685>.
- 494 [15] Fialová D, Topinková E, Gambassi G, Finne-Soveri H, Jónsson PV, Carpenter I, et al.  
495 Potentially Inappropriate Medication Use Among Elderly Home Care Patients in Europe. *JAMA*  
496 2005;293:1348–58. <https://doi.org/10.1001/jama.293.11.1348>.
- 497 [16] Jirón M, Pate V, Hanson LC, Lund JL, Jonsson Funk M, Stürmer T. Trends in Prevalence and  
498 Determinants of Potentially Inappropriate Prescribing in the United States: 2007 to 2012. *J Am*  
499 *Geriatr Soc* 2016;64:788–97. <https://doi.org/10.1111/jgs.14077>.
- 500 [17] Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health  
501 improvement network (THIN) database for pharmacoepidemiology research. *Pharmacoepidemiol*  
502 *Drug Saf* 2007;16:393–401. <https://doi.org/10.1002/pds.1335>.
- 503 [18] Faquetti ML, la Torre AM, Burkard T, Obozinski G, Burden AM. Identification of  
504 polypharmacy patterns in new-users of metformin using the Apriori algorithm: A novel framework  
505 for investigating concomitant drug utilization through association rule mining. *Pharmacoepidemiol*  
506 *Drug Saf* 2023;pds.5583. <https://doi.org/10.1002/pds.5583>.
- 507 [19] Guillot J, Maumus-Robert S, Marceron A, Noize P, Pariente A, Bezin J. The Burden of  
508 Potentially Inappropriate Medications in Chronic Polypharmacy. *J Clin Med* 2020;9:3728.  
509 <https://doi.org/10.3390/jcm9113728>.
- 510 [20] Ble A, Masoli JAH, Barry HE, Winder RE, Tavakoly B, Henley WE, et al. Any versus long-term  
511 prescribing of high risk medications in older people using 2012 Beers Criteria: results from three  
512 cross-sectional samples of primary care records for 2003/4, 2007/8 and 2011/12. *BMC Geriatr*  
513 2015;15:146. <https://doi.org/10.1186/s12877-015-0143-8>.

- 514 [21] Cooper JA, Moriarty F, Ryan C, Smith SM, Bennett K, Fahey T, et al. Potentially inappropriate  
515 prescribing in two populations with differing socio-economic profiles: a cross-sectional database  
516 study using the PROMPT criteria. *Eur J Clin Pharmacol* 2016;72:583–91.  
517 <https://doi.org/10.1007/s00228-015-2003-z>.
- 518 [22] Moriarty F, Cahir C, Bennett K, Hughes CM, Kenny RA, Fahey T. Potentially inappropriate  
519 prescribing and its association with health outcomes in middle-aged people: a prospective cohort  
520 study in Ireland. *BMJ Open* 2017;7:e016562. <https://doi.org/10.1136/bmjopen-2017-016562>.
- 521 [23] Davidoff AJ, Miller GE, Sarpong EM, Yang E, Brandt N, Fick DM. Prevalence of Potentially  
522 Inappropriate Medication Use in Older Adults Using the 2012 Beers Criteria. *J Am Geriatr Soc*  
523 2015;63:486–500. <https://doi.org/10.1111/jgs.13320>.
- 524 [24] Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications  
525 use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria.  
526 *BMC Geriatr* 2019;19:154. <https://doi.org/10.1186/s12877-019-1168-1>.
- 527 [25] Thomas RE, Thomas BC. A Systematic Review of Studies of the STOPP/START 2015 and  
528 American Geriatric Society Beers 2015 Criteria in Patients  $\geq$  65 Years. *Curr Aging Sci* 2019;12:121–54.  
529 <https://doi.org/10.2174/1874609812666190516093742>.
- 530 [26] Yang H, Juang S-Y, Liao K-F. Proton pump inhibitors use and risk of chronic kidney disease in  
531 diabetic patients. *Diabetes Res Clin Pract* 2019;147:67–75.  
532 <https://doi.org/10.1016/j.diabres.2018.11.019>.
- 533 [27] Scarpignato C, Gatta L, Zullo A, Blandizzi C, Scarpignato C, Blandizzi C, et al. Effective and safe  
534 proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and  
535 potential harms of acid suppression. *BMC Med* 2016;14:179. [https://doi.org/10.1186/s12916-016-](https://doi.org/10.1186/s12916-016-0718-z)  
536 0718-z.
- 537 [28] Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors:  
538 what the clinician needs to know. *Ther Adv Gastroenterol* 2012;5:219–32.  
539 <https://doi.org/10.1177/1756283X12437358>.
- 540 [29] Boath EH, Blenkinsopp A. The rise and rise of proton pump inhibitor drugs: patients’  
541 perspectives. *Soc Sci Med* 1982 1997;45:1571–9. [https://doi.org/10.1016/s0277-9536\(97\)00094-4](https://doi.org/10.1016/s0277-9536(97)00094-4).
- 542 [30] Pottegård A, Broe A, Hallas J, de Muckadell OBS, Lassen AT, Lødrup AB. Use of proton-pump  
543 inhibitors among adults: a Danish nationwide drug utilization study. *Ther Adv Gastroenterol*  
544 2016;9:671–8. <https://doi.org/10.1177/1756283X16650156>.


- 545 [31] van Eijk MEC, Bahri P, Dekker G, Herings RMC, Porsius A, Avorn J, et al. Use of prevalence  
546 and incidence measures to describe age-related prescribing of antidepressants with and without  
547 anticholinergic effects. *J Clin Epidemiol* 2000;53:645–51. [https://doi.org/10.1016/S0895-](https://doi.org/10.1016/S0895-4356(99)00194-8)  
548 4356(99)00194-8.
- 549 [32] Beers MH, Ouslander JG. Risk Factors in Geriatric Drug Prescribing: A Practical Guide to  
550 Avoiding Problems. *Drugs* 1989;37:105–12. <https://doi.org/10.2165/00003495-198937010-00008>.
- 551 [33] Nolan L, O'Malley K. Adverse Effects of Antidepressants in the Elderly. *Drugs Aging*  
552 1992;2:450–8. <https://doi.org/10.2165/00002512-199202050-00008>.
- 553 [34] Krolewski AS, Warram JH, Cupples A, Gorman CK, Szabo AJ, Christlieb AR. Hypertension,  
554 orthostatic hypotension and the microvascular complications of diabetes. *J Chronic Dis*  
555 1985;38:319–26. [https://doi.org/10.1016/0021-9681\(85\)90078-5](https://doi.org/10.1016/0021-9681(85)90078-5).
- 556 [35] De Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and  
557 Hypertension: A Position Statement by the American Diabetes Association. *Diabetes Care*  
558 2017;40:1273–84. <https://doi.org/10.2337/dci17-0026>.
- 559 [36] National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and  
560 management, <https://www.nice.org.uk/guidance/ng222>; 2022 [accessed 20 April 2023].
- 561 [37] Airagnes G, Pelissolo A, Lavallée M, Flament M, Limosin F. Benzodiazepine Misuse in the  
562 Elderly: Risk Factors, Consequences, and Management. *Curr Psychiatry Rep* 2016;18:89.  
563 <https://doi.org/10.1007/s11920-016-0727-9>.
- 564 [38] Scharner V, Hasieber L, Sönnichsen A, Mann E. Efficacy and safety of Z-substances in the  
565 management of insomnia in older adults: a systematic review for the development of  
566 recommendations to reduce potentially inappropriate prescribing. *BMC Geriatr* 2022;22:87.  
567 <https://doi.org/10.1186/s12877-022-02757-6>.
- 568 [39] Darowski A, Chambers S-ACF, Chambers DJ. Antidepressants and Falls in the Elderly: *Drugs*  
569 *Aging* 2009;26:381–94. <https://doi.org/10.2165/00002512-200926050-00002>.
- 570 [40] Dell'osso B, Lader M. Do Benzodiazepines Still Deserve a Major Role in The Treatment of  
571 Psychiatric Disorders? A Critical Reappraisal. *Eur Psychiatry* 2013;28:7–20.  
572 <https://doi.org/10.1016/j.eurpsy.2011.11.003>.
- 573 [41] National Institute for Health and Care Excellence (NICE). Chronic pain (primary and  
574 secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain,  
575 <https://www.nice.org.uk/guidance/ng193>; 2021 [accessed 11 April 2023].

- 576 [42] Ensrud KE. Epidemiology of Fracture Risk With Advancing Age. *J Gerontol A Biol Sci Med Sci*  
577 2013;68:1236–42. <https://doi.org/10.1093/gerona/glt092>.
- 578 [43] Yang Y, Hu X, Zhang Q, Zou R. Diabetes mellitus and risk of falls in older adults: a systematic  
579 review and meta-analysis. *Age Ageing* 2016;45:761–7. <https://doi.org/10.1093/ageing/afw140>.
- 580 [44] Wertli MM. Opioid Prescription in Switzerland: Appropriate Comedication use in Cancer and  
581 Noncancer Pain. *Pain Physician* 2019;6:537–48. <https://doi.org/10.36076/ppj/2019.22.537>.
- 582 [45] Masclee GMC, Valkhoff VE, Coloma PM, De Ridder M, Romio S, Schuemie MJ, et al. Risk of  
583 Upper Gastrointestinal Bleeding From Different Drug Combinations. *Gastroenterology*  
584 2014;147:784-792.e9. <https://doi.org/10.1053/j.gastro.2014.06.007>.
- 585 [46] Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage:epidemiology,  
586 prevention and treatment. *Curr Med Res Opin* 2007;23:163–73.  
587 <https://doi.org/10.1185/030079907X162656>.
- 588 [47] Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective Serotonin Reuptake  
589 Inhibitors Are Associated With a Modest Increase in the Risk of Upper Gastrointestinal Bleeding. *Am*  
590 *J Gastroenterol* 2009;104:1475–82. <https://doi.org/10.1038/ajg.2009.128>.
- 591 [48] Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising  
592 potentially inappropriate medications in adults: a systematic review and thematic synthesis. *BMJ*  
593 *Open* 2014;4:e006544. <https://doi.org/10.1136/bmjopen-2014-006544>.
- 594 [49] Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, et al. Deprescribing  
595 benzodiazepine receptor agonists. *Can Fam Physician* 2018;64:339–51.
- 596 [50] Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing  
597 proton pump inhibitors: Evidence-based clinical practice guideline. *Can Fam Physician* 2017;63:354–  
598 64.
- 599 [51] Beers MH. Explicit Criteria for Determining Potentially Inappropriate Medication Use by the  
600 Elderly: An Update. *Arch Intern Med* 1997;157:1531–6.  
601 <https://doi.org/10.1001/archinte.1997.00440350031003>.
- 602 [52] East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal  
603 CCG, South Kent Coast CCG and Thanet CCG), National Health Service (NHS). Long-term  
604 nitrofurantoin safety monitoring guidance for prescribers,  
605 [https://www.eastkentformulary.nhs.uk/media/1539/ekpg\\_nitrofurantoin-safety-](https://www.eastkentformulary.nhs.uk/media/1539/ekpg_nitrofurantoin-safety-monitoring-guidance-patients-final-jan2020.pdf)  
606 [monitoring-guidance-patients-final-jan2020.pdf](https://www.eastkentformulary.nhs.uk/media/1539/ekpg_nitrofurantoin-safety-monitoring-guidance-patients-final-jan2020.pdf); 2020 [accessed 11 April 2023].

- 607 [53] National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults:  
608 pharmacological management in non-specialist settings, <https://www.nice.org.uk/guidance/cg173>;  
609 2013 [accessed 14 April 2023].
- 610 [54] O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria  
611 for potentially inappropriate prescribing in older people: version 2. *Age Ageing* 2014;44:213–8.  
612 <https://doi.org/10.1093/ageing/afu145>.

613 Figures

614



615

616

617 **Figure 1.** Flow diagram of patient selection. NIAD, non-insulin antidiabetic drug.

618 Tables

619

620 **Table 1.** Baseline characteristics of non-insulin antidiabetic drug (NIAD) new-users, stratified by age  
621 and polypharmacy status.

Characteristic	Overall study cohort (N = 28,604)		Middle-aged (≥45 and <65 years) (N = 16,654)		Older adults (≥65 years) (N = 11,950)	
	no polypharmacy	polypharmacy	no polypharmacy	polypharmacy	No polypharmacy	Polypharmacy
<b>N (%)</b>	10,110 (35.3%)	18,494 (64.7%)	7,457 (44.8%)	9,197 (55.2%)	2,653 (22.2%)	9,297 (77.8%)
<b>Females</b>	3,462 (34.2%)	8,429 (45.6%)	2,446 (32.8%)	4,163 (45.3%)	1,016 (38.3%)	4,266 (45.9%)
<b>Mean age (SD)</b>	58.8 (9.3)	64.9 (10.8)	54.3 (5.4)	55.9 (5.4)	71.4 (5.5)	73.7 (6.6)
<b>Median number of drugs (IQR)</b>	3 (2 – 4)	8 (6 – 11)	3 (2 – 4)	8 (6 – 11)	3 (2 – 4)	8 (6 – 11)
<b>Mean number of drugs (SD)</b>	2.7 (1.1)	9.1 (4.0)	2.6 (1.1)	8.8 (4.0)	3.0 (1.0)	9.5 (4.0)
<b>Distribution of drugs n (%)</b>						
1 (NIAD)	1,653 (5.8%)	-	1,376 (8.2%)	-	277 (2.3%)	-
2 - 4	8,457 (29.6%)	-	6,081 (36.5%)	-	2,376 (19.9%)	-
5 - 9	-	11,848 (41.4%)	-	6,259 (37.6%)	-	5,589 (46.8%)
10 - 19	-	6,180 (21.6%)	-	2,714 (16.3%)	-	3,466 (29.0%)
≥ 20	-	466 (1.6%)	-	224 (1.3%)	-	242 (2.0%)
Max n° of drugs	4	41	4	41	4	40
<b>Number of NIADs prescribed at index date n (%)</b>						
≥ 2	293 (2.9%)	557 (3.0%)	230 (3.1%)	348 (3.8%)	63 (2.4%)	209 (2.2%)
<b>NIAD class<sup>1</sup></b>						
Biguanides (Metformin)	9,611 (96.8%)	17,082 (94.5%)	7,231 (97.0%)	8,890 (96.7%)	2,551 (96.2%)	8,592 (92.4%)
Sulfonylureas	615 (6.2%)	1,319 (7.4%)	472 (6.3%)	659 (7.2%)	157 (5.9%)	712 (7.7%)
DPP-4 inhibitors	112 (1.1%)	503 (2.8%)	61 (0.8%)	125 (1.4%)	53 (2.0%)	393 (4.2%)
SGLT-2 inhibitors	47 (0.5%)	115 (0.6%)	45 (0.6%)	77 (0.8%)	<7	40 (0.4%)
GLP-1 analogues	10 (0.1%)	22 (0.1%)	12 (0.2%)	18 (0.2%)	<7	<7
Thiazolidinediones	8 (0.08%)	12 (0.06%)	<7	<7	<7	7 (0.8%)
Others	7 (0.07%)	18 (0.1%)	<7	14 (0.2%)	<7	<7
<b>Smoking status<sup>2</sup>, n (%)</b>						
Current	1,629 (16.1%)	3,243 (17.5%)	1,336 (17.9%)	2,242 (24.4%)	293 (11.0%)	1,001 (10.8%)
Never	5,513 (54.5%)	8,096 (43.8%)	4,080 (54.7%)	3,897 (42.4%)	1,433 (54.0%)	4,199 (45.2%)
Former	2,910 (28.8%)	7,079 (38.3%)	2,003 (26.9%)	3,012 (32.7%)	907 (34.2%)	4,067 (43.7%)
Unknown / Missing value	58 (0.6%)	76 (0.4%)	38 (0.5%)	46 (0.5%)	20 (0.8%)	30 (0.3%)
<b>Alcohol use<sup>2</sup>, n (%)</b>						
Current	7,313 (72.3%)	11,950 (64.6%)	5,412 (72.6%)	6,030 (65.6%)	1,901 (71.7%)	5,920 (63.7%)
Never (Lifelong teetotaler)	1,826 (18.1%)	4,590 (24.8%)	1,332 (17.9%)	2,146 (23.3%)	494 (18.6%)	2,444 (26.3%)
Former	322 (3.2%)	1,187 (6.4%)	219 (2.9%)	591 (6.4%)	103 (3.9%)	596 (6.4%)
Unknown / Missing value	649 (6.4%)	767 (4.1%)	494 (6.6%)	430 (4.7%)	155 (5.8%)	337 (3.6%)
<b>BMI<sup>3</sup>, n (%)</b>						
Obese (BMI ≥30.0 kg/m <sup>2</sup> )	5,921 (58.6%)	12,083 (65.3%)	4,675 (62.7%)	6,862 (74.6%)	1,246 (47.0%)	5,221 (56.1%)
Overweight (BMI 25.0 – 29.9 kg/m <sup>2</sup> )	2,944 (29.1%)	4,616 (25.0%)	1,973 (26.5%)	1,708 (18.6%)	971 (36.6%)	2,908 (31.3%)
Normal/ Underweight (BMI < 25.0 kg/m <sup>2</sup> )	878 (8.7%)	1,380 (7.5%)	540 (7.2%)	404 (4.4%)	338 (12.7%)	976 (10.5%)
Missing value	367 (3.6%)	415 (2.2%)	269 (3.6%)	223 (2.4%)	98 (3.7%)	192 (2.1%)

622



623 **Table 1.** Continued.

<b>History of disease, n (%)</b>						
Hypertension	3,246 (32.1%)	11,409 (61.7%)	2,321 (28.5%)	4,939 (53.7%)	1,123 (42.3%)	6,470 (69.6%)
Coronary heart disease	172 (1.7%)	3,780 (20.4%)	90 (1.2%)	1,373 (14.9%)	82 (3.1%)	2,407 (25.9%)
Heart failure	10 (0.1%)	782 (4.2%)	<7	234 (2.5%)	<7	548 (5.9%)
Cerebrovascular disease	185 (1.8%)	1,773 (9.6%)	101 (1.4%)	561 (6.1%)	84 (3.2%)	1,212 (13.0%)
Chronic kidney disease	376 (3.7%)	2,558 (13.8%)	156 (2.1%)	504 (5.5%)	220 (8.3%)	2,054 (22.1%)
Chronic liver disease	257 (2.5%)	823 (4.5%)	192 (2.6%)	496 (5.4%)	65 (2.5%)	327 (3.5%)
COPD	208 (2.1%)	2,408 (13.0%)	114 (1.5%)	922 (10.0%)	94 (3.5%)	1,486 (16.0%)
Asthma	810 (8.0%)	3,703 (20.0%)	653 (8.8%)	2,056 (22.4%)	57 (5.9%)	1,617 (17.7%)
Sleep disorders	707 (7.0%)	2,847 (15.4%)	566 (7.6%)	1,604 (17.4%)	141 (5.3%)	1,243 (13.4%)
Depression	1,993 (19.7%)	6,655 (36.0%)	1,600 (21.5%)	4,013 (43.6%)	393 (14.8%)	2,642 (28.4%)
Alzheimer/Dementia	39 (0.4%)	406 (2.2%)	12 (0.2%)	32 (0.3%)	27 (1.0%)	374 (4.0%)
Hypothyroidism	426 (4.2%)	2,224 (12.0%)	281 (3.8%)	978 (10.6%)	145 (5.5%)	1,246 (13.4%)
Osteoarthritis	1,169 (11.6%)	5,003 (27.1%)	592 (7.9%)	1,621 (17.6%)	577 (21.7%)	3,382 (36.4%)
Osteoporosis	94 (0.9%)	829 (4.5%)	32 (0.4%)	169 (1.8%)	62 (2.3%)	660 (7.1%)
<b>Lab values</b>						
<b>Most recent HbA<sub>1c</sub> measurement six months prior to index date n (%)<sup>4</sup></b>						
<6.5% (48 mmol/mol)	304 (3.0%)	647 (3.5%)	235 (3.2%)	325 (3.5%)	69 (2.6%)	322 (3.5%)
6.5 – 7.4% (48 – 57 mmol/mol)	2,410 (23.8%)	5,594 (30.2%)	1,672 (22.4%)	2,618 (28.5%)	738 (27.8%)	2,976 (32.0%)
7.5 – 8.5% (58 – 69 mmol/mol)	2,010 (19.9%)	4,614 (24.9%)	1,389 (18.6%)	2,087 (22.7%)	621 (23.4%)	2,527 (27.2%)
>8.5% (69 mmol/mol)	4,419 (43.7%)	5,781 (31.3%)	3,429 (46.0%)	3,211 (34.9%)	990 (37.3%)	2,570 (27.6%)
Missing value	967 (9.6%)	1,858 (10.0%)	732 (9.8%)	956 (10.4%)	235 (8.9%)	902 (9.7%)
<b>Most recent eGFR measurement (mL/min/1.73 m<sup>2</sup>) six months prior to index date n (%)<sup>4</sup></b>						
< 30	8 (0.1%)	73 (0.4%)	<7	13 (0.1%)	<7	60 (0.6%)
30 – 59	452 (4.5%)	2,406 (13.0%)	184 (2.5%)	499 (5.4%)	268 (10.1%)	1,907 (20.5%)
≥60	6,886 (68.1%)	11,188 (60.5%)	5,190 (69.6%)	6,067 (66.0%)	1,696 (63.9%)	5,121 (55.1%)
Missing value	2,764 (27.3%)	4,827 (27.6%)	2,083 (27.9%)	2,618 (28.5%)	683 (25.7%)	2,209 (23.8%)

624 <sup>1</sup> The summed proportion value is above 100%, as a patient may receive more than one NIAD compound at the index date.

625 <sup>2</sup> Identified values closest to the index date (i.e., at or before index date).

626 <sup>3</sup> BMI was assessed using the most recently recorded value for weight (at or at any time before index date) and height (at or at any time before or  
627 after index date).

628 <sup>4</sup> The most recent value (at index date and previous six-months) registered in the database with a valid unit was considered.

629 **Abbreviations:** NIAD: non-insulin antidiabetic drug; SD: standard deviation; IQR: interquartile range; DPP-4: Dipeptidyl peptidase 4; SGLT-2: Sodium-  
630 glucose co-transporter 2; GLP-1: Glucagon-like peptide-1; BMI: body mass index; COPD: chronic obstructive pulmonary disease; HbA<sub>1c</sub>: hemoglobin  
631 A<sub>1c</sub>; eGFR: Estimated glomerular filtration rate;

632 **Note:** A history of comorbidities was assessed if ever registered in the database previous to or at index date. Numbers fewer than seven are  
633 suppressed according to data use agreement with IMRD.

634

635 **Table 2.** Prevalence of potentially inappropriate prescriptions (PIPs) in middle-aged and older adults  
636 according to the American Geriatrics Society (AGS) Beers criteria 2015 and the Prescribing Optimally  
637 in Middle-aged People’s Treatments (PROMPT) criteria, respectively, stratified by polypharmacy  
638 status.

Age group	Older adults (≥65 years)		Middle-aged (≥45 and <65 years)	
	No polypharmacy (N=2,653)	Polypharmacy (N= 9,297)	No polypharmacy (N= 7,457)	Polypharmacy (N= 9,297)
0	2,480 (93.5%)	5,615 (60.4%)	7,342 (98.5%)	7,113 (77.3%)
1	142 (5.4%)	2,488 (26.8%)	*	1,535 (16.7%)
2	25 (0.9%)	701 (7.5%)	*	425 (4.6%)
3	<7	179 (1.9%)	0 (0.0%)	108 (1.2%)
4	<7	103 (1.1%)	0 (0.0%)	16 (0.2%)
≥5	0 (0.0%)	211 (2.3%)	0 (0.0%)	0 (0.0%)
max	4	10	2	4
≥1	173 (6.5%)	3,682 (39.6%)	114 (1.5%)	2,084 (22.7%)

639 \* These numbers were suppressed due to patient privacy.

640 **Abbreviations:** PIPs: Potentially inappropriate prescriptions.

641

642 **Table 3.** Prevalence of individual potentially inappropriate prescriptions (PIPs) in older adults with  
 643 new-onset type 2 diabetes (T2DM) according to the American Geriatrics Society (AGS) Beers criteria  
 644 2015, stratified by polypharmacy status.

Table Number <sup>1</sup>	Criteria Number	Recommendation	Patients receiving PIP without polypharmacy (N=2,653)	Patients receiving PIP with polypharmacy (N= 9,297)	Sensitivity Analysis (Patients with dosage information) <sup>2</sup>	
					Patients receiving PIP without polypharmacy (N=2,653)	Patients receiving PIP with polypharmacy (N= 9,297)
2	1	Avoid first generation AH	<7	170 (1.8%)		
2	2	Avoid antiparkinsonian agents in combination with antipsychotics	0 (0.0%)	0 (0.0%)		
2	3	Avoid antispasmodics	<7	90 (1.0%)		
2	4	Avoid dipyridamole oral short-action	0 (0.0%)	<7		
2	5	Avoid ticlopidine	0 (0.0%)	0 (0.0%)		
2	6	Avoid nitrofurantoin if (i) creatinine clearance <30ml/min or (ii) long-term suppression of bacteria	0 (0.0%) <sup>(i)</sup> 0 (0.0%) <sup>(ii)</sup>	20 (0.2%) <sup>(i)</sup> 37 (0.4%) <sup>(ii)</sup>	0 (0.0%) <sup>(iii)</sup>	23 (0.2%) <sup>(iii)</sup>
2	7	Avoid peripheral alpha-1 blockers in hypertension	13 (0.5%)	495 (5.3%)		
2	8	Avoid clonidine (as first-line therapy), guanabenz, guanfacine, methyl dopa and reserpine (>0.1 mg/day) in hypertension	0 (0.0%)	<7		
2	9	Avoid disopyramide	0 (0.0%)	<7		
2	10	Avoid dronedarone in permanent AF or severe/recently decompensated HF	0 (0.0%)	0 (0.0%)		
2	11	Avoid digoxin as first-line therapy for AF	0 (0.0%)	36 (0.4%)		
2	12	Avoid digoxin as first-line therapy for HF	0 (0.0%)	<7		
2	13	If digoxin is used for AF or HF, avoid dosages >125 mcg/day	<7	72 (0.8%)	<7	72 (0.8%)
2	14	Avoid nifedipine immediate release	0 (0.0%)	13 (0.1%)		
2	15	Avoid amiodarone as first-line therapy for AF unless patient has HF or substantial left ventricular hypertrophy	0 (0.0%)	<7		
2	16	Avoid antidepressants <sup>3</sup> alone or in combination	31 (1.2%)	951 (10.2%)		
2	17	Avoid first- and second- generation antipsychotics (except for schizophrenia, bipolar disorder, or short-term use as antiemetic during chemotherapy)	24 (0.9%)	333 (3.6%)		
2	18	Avoid barbiturates	<7	<7		
2	19	Avoid short- and intermediate-acting BZD	<7	139 (1.5%)		
2	20	Avoid long-acting BZD	10 (0.4%)	333 (3.6%)		
2	21	Avoid meprobamate	0 (0.0%)	0 (0.0%)		
2	22	Avoid BZD-receptor agonist hypnotics	<7	330 (3.5%)		
2	23	Avoid Ergoloid mesylates and isoxsuprine	0 (0.0%)	0 (0.0%)		

646 **Table 3.** Continued.

2	24	Avoid androgens unless hypogonadism	0 (0.0%)	23 (0.2%)		
2	25	Avoid desiccated thyroid	0 (0.0%)	0 (0.0%)		
2	26	Avoid oral and topical patch estrogens	<7	34 (0.4%)		
2	27	Avoid GH, except as hormone replacement after pituitary gland removal	0 (0.0%)	<7		
2	28	Avoid megestrol	0 (0.0%)	0 (0.0%)		
2	29	Avoid long duration SU (chlorpropamide)	0 (0.0%)	0 (0.0%)		
2	30	Avoid long duration SU (glyburide)	0 (0.0%)	<7		
2	31	Avoid metoclopramide unless gastroparesis	<7	65 (0.7%)		
2	32	Avoid mineral oil given orally	0 (0.0%)	0 (0.0%)		
2	33	Avoid PPI use for >8weeks	46 (1.7%)	1,034 (11.1%)	30 (1.1%)	772 (8.3%)
2	34	Avoid meperidine, especially in individuals with CKD	0 (0.0%)	0 (0.0%)		
2	35	Avoid chronic use of oral non-cyclooxygenase-NSAID	<7	29 (0.3%)	0 (0.0%)	12 (0.1%)
2	36	Avoid indomethacin, ketorolac (including parenteral)	<7	16 (0.2%)		
2	37	Avoid pentazocine	0 (0.0%)	0 (0.0%)		
2	38	Avoid skeletal muscle relaxants <sup>4</sup>	0 (0.0%)	15 (0.2%)		
2	39	Avoid desmopressin for treatment of nocturia or nocturnal polyuria	0 (0.0%)	<7		
3	40	In patients with HF, avoid (i) NSAID, COX-2 inhibitors, thiazolidinediones (pioglitazone, rosiglitazone), and cilostazol, (ii) dronedarone in severe or recently decompensated HF, and (iii) nondihydropyridine CCB (diltiazem, verapamil) only in patients with HFrEF.	0 (0.0%) <sup>(i)</sup> 0 (0.0%) <sup>(ii)</sup> NA <sup>(iii)</sup>	18 (0.2%) <sup>(i)</sup> 0 (0.0%) <sup>(ii)</sup> NA <sup>(iii)</sup>		
3	41	Avoid AchEi, peripheral alpha-1 blockers, tertiary TCA, chlorpromazine, thioridazine, olanzapine in patients with syncope	0 (0.0%)	<7		
3	42	Avoid bupropion, chlorpromazine, clozapine, maprotiline, olanzapine, thioridazine, thiothixene, and tramadol if chronic seizures or epilepsy	<7	<7		
3	43	Avoid (i) anticholinergics, BZD chlorpromazine, corticosteroids, H2-receptor blockers, meperidine, sedative hypnotics in patients with or at risk of delirium. Avoid (ii) antipsychotics for behavioral problems of dementia or delirium.	0 (0.0%) <sup>(i)</sup> <7 <sup>(ii)</sup>	14 (0.2%) <sup>(i)</sup> 46 (0.5%) <sup>(ii)</sup>		
3	44	Avoid anticholinergics, antipsychotics, H2-receptor antagonist, BZD, non-BZD, BZD receptor agonist hypnotics in patients with dementia or cognitive impairment	<7	232 (2.5%)		

647 **Table 3.** Continued.

3	45	In patients with history of falls or fractures, avoid (i) anticonvulsants (except for seizure and mood disorders), (ii) antipsychotics, BZD, non- BZD, BZD receptor agonist hypnotics, TCA, SSRI (unless safer alternatives are not available) <sup>5</sup> , and (iii) opioids (except for pain management due to recent fractures or joint replacement).	<7 <sup>(i)</sup> 35 (1.3%) <sup>(ii)</sup> 8 (0.3%) <sup>(iii)</sup>	144 (1.5%) <sup>(i)</sup> 911 (9.8%) <sup>(ii)</sup> 379 (4.1%) <sup>(iii)</sup>
3	46	Avoid CNS stimulants (oral decongestants, stimulants, and theobromines) in patients with insomnia	0 (0.0%)	65 (0.7%)
3	47	Antipsychotics (except aripiprazole, quetiapine, and clozapine) and antiemetics in patients with Parkinson's disease avoid	0 (0.0%)	7 (0.1%)
3	48	Avoid aspirin (>325 mg/day) and non-COX2 NSAID in patients with history of gastric ulcers unless other alternatives are not effective and patient can take gastroprotective agent	0 (0.0%)	7 (0.1%)
3	49	Avoid NSAID (non-COX and COX-selective, oral and parenteral) in CKD stages IV or less	0 (0.0%)	0 (0.0%)
3	50	Avoid estrogen (oral and transdermal) and peripheral alpha-1 blockers in women with urinary incontinency	0 (0.0%)	0 (0.0%)
3	51	Avoid strong anticholinergics drugs (except antimuscarinics for urinary incontinence) in men with lower urinary tract symptoms or BPH	0 (0.0%)	17 (0.2%)
5	52	Avoid use of ACE inhibitors and amiloride or triamterene;	0 (0.0%)	<7
5	53	Avoid using $\geq 2$ anticholinergic drugs	0 (0.0%)	0 (0.0%)
5	54	Avoid SSRI <sup>(i)</sup> or TCA <sup>(ii)</sup> and $\geq 2$ other CNS-active drugs	<7 0 (0.0%)	163 (1.8%) <sup>(i)</sup> 142 (1.5%) <sup>(ii)</sup>
5	55	Avoid antipsychotics and $\geq 2$ other CNS-active drugs	<7	86 (0.9%)
5	56	Avoid BZD and non-BZD, BZD receptor agonist hypnotics and $\geq 2$ additional CNS-active drugs	0 (0.0%)	197 (2.1%)
5	57	Avoid corticosteroids + NSAID, if not possible, provide GI protection	0 (0.0%)	22 (0.2%)
5	58	Avoid lithium together with ACE inhibitors, monitor lithium concentration	0 (0.0%)	7 (0.1%)
5	59	Avoid lithium together with loop diuretics, monitor lithium concentration	0 (0.0%)	<7
5	60	Avoid opioids and $\geq 2$ other CNS-active drugs	<7	214 (2.3%)
5	61	Avoid peripheral alpha-1 blockers together with loop diuretics in older women unless conditions warrant both drugs	0 (0.0%)	19 (0.2%)

648 **Table 3.** Continued.

5	62	Avoid theophylline in combination with cimetidine	0 (0.0%)	0 (0.0%)
5	63	Avoid warfarin in combination with amiodarone when possible	0 (0.0%)	11 (0.1%)
5	64	Avoid warfarin in combination with NSAID when possible	0 (0.0%)	<7
5	65	Avoid amiodarone if creatinine clearance <30 mL/min	0 (0.0%)	<7
6	66	Avoid apixaban if creatinine clearance <25 mL/min	0 (0.0%)	<7
6	67	Avoid dabigatran if creatinine clearance <30 mL/min	0 (0.0%)	<7
6	68	Avoid edoxaban if creatinine clearance <30 or >95 mL/min	0 (0.0%)	<7
6	69	Avoid fondaparinux if creatinine clearance <30 mL/min	0 (0.0%)	0 (0.0%)
6	70	Avoid rivaroxaban if creatinine clearance <30 mL/min	0 (0.0%)	<7
6	71	Avoid spironolactone if creatinine clearance <30 mL/min	0 (0.0%)	11 (0.1%)
6	72	Avoid triamterene if creatinine clearance <30 mL/min	0 (0.0%)	0 (0.0%)
6	73	Avoid duloxetine if creatinine clearance <30 mL/min	0 (0.0%)	<7
6	74	Avoid tramadol extended release if creatinine clearance <30 mL/min	0 (0.0%)	0 (0.0%)
6	75	Avoid probenecid if creatinine clearance <30 mL/min	0 (0.0%)	0 (0.0%)

649 <sup>1</sup> Original table number from the 2015 Beers criteria (doi: 10.1111/jgs.13702)

650 <sup>2</sup> Drugs of which judgment of PIP was dependant on prescribed dose or duration, prevalence of PIPs was reported separately for patients having complete information on dose or duration.

652 <sup>3</sup> Amitriptyline, amoxapine, clomipramine, desipramine, doxepin (>6mg/day), imipramine, nortriptyline, paroxetine, protriptyline, trimipramine.

653 <sup>4</sup> Carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine.

654 <sup>5</sup> Criteria partially applied (detailed information at the Supplementary Information Table S1).

655 **Abbreviations:** ACE: Angiotensin-converting enzyme ; AchEi: acetylcholinesterase inhibitors; AH: Anti-histamine; AF: Atrial fibrillation; ARB:  
656 Angiotensin II receptor blockers; BB: Beta blockers; BPH: Benign prostatic hyperplasia; BZD: Benzodiazepines; CCB: calcium-channel blockers; CKD:  
657 Chronic kidney disease; CNS: Central nervous system; GH: Growth hormone; GI: Gastrointestinal; HF: Heart failure; HFrEF: Heart failure with reduced  
658 ejection fraction; NA: Not assessed; NSAID: non-steroidal anti-inflammatory drugs; PIP: Potentially inappropriate prescription; PPI: Proton pump  
659 inhibitor; SSRI: selective serotonin reuptake inhibitor; SU: sulfonyleureas; TCA: Tricyclic antidepressants;

660 **Table 4.** Prevalence of individual potentially inappropriate prescriptions (PIPs) in middle-aged adults  
 661 with new-onset type 2 diabetes (T2DM) according to the Prescribing Optimally in Middle-aged  
 662 People’s Treatments (PROMPT) criteria, stratified by polypharmacy status.

Criteria Number	Recommendation	Patients receiving PIP without polypharmacy (N= 7,457)	Patients receiving PIP with polypharmacy (N= 9,197)	Sensitivity Analysis (Patients with dosage information <sup>1</sup> )	
				Patients receiving PIP without polypharmacy (N= 7,457)	Patients receiving PIP with polypharmacy (N= 9,197)
1	Avoid stimulant laxatives as first-line treatment in constipation for >4 weeks other than for opioid-induced constipation	<7	25 (0.3%)	<7	10 (0.1%)
2	Avoid PPI above recommended maintenance dose for >8 weeks	13 (0.2%)	269 (2.9%)	13 (0.2%)	269 (2.9%)
3	Avoid omeprazole and esomeprazole in combination with clopidogrel	0 (0.0%)	107 (1.2%)		
4	Avoid use of alpha-adrenoceptor blocking drugs as monotherapy for hypertension.	8 (0.1%)	<7		
5	Aspirin dose should not exceed 150 mg/ day for anti-platelet therapy	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
6	Avoid cardio selective CCB in combination with BB	0 (0.0%)	27 (0.3%)		
7	Avoid oral short-acting dipyridamole as monotherapy in antiplatelet treatment	0 (0.0%)	0 (0.0%)		
8	Avoid first-generation anti-histamines as first-line treatment for >7 days.	14 (0.2%)	185 (2.0%)	9 (0.1%)	108 (1.2%)
9	Avoid theophylline monotherapy for asthma or COPD	0 (0.0%)	<7		
10	Concomitant bisphosphonate if oral corticosteroids >3 months	11 (0.1%)	113 (1.2%)	<7	30 (0.3%)
11	Avoid mucolytic agents in stable COPD	<7	65 (0.7%)		
12	Avoid SSRI + venlafaxine	0 (0.0%)	8 (0.08%)		
13	Avoid TCA as first-line treatment of depression	7 (0.09%)	101 (1.1%)		
14	Avoid BZD long term use	<7	293 (3.2%)	<7	131 (1.4%)
15	Avoid non-BZD hypnotics long term use	7 (0.09%)	245 (2.7%)	<7	127 (1.4%)
16	Avoid carbamazepine with clarithromycin or erythromycin	0 (0.0%)	<7		
17	Strong opioids should be prescribed together with laxatives	11 (0.1%)	381 (4.1%)		
18	Avoid nitrofurantoin >7 days in the treatment of uncomplicated lower UTI	10 (0.1%)	32 (0.3%)	<7	19 (0.2%)
19	Avoid use of long acting SU	0 (0.0%)	0 (0.0%)		
20	Avoid long term NSAID	11 (0.1%)	283 (3.1%)	<7	119 (1.3%)
21	Avoid combination of NSAID and 1) low dose aspirin or 2) SSRI, without adequate gastrointestinal protection	8 (0.1%)	361 (3.9%)		
22	Avoid ≥2+ drugs from the same pharmacological class – Example 1: Opioids (excl. morphine and methadone)	0 (0.0%)	204 (2.2%)		
22	Avoid ≥2+ drugs from the same pharmacological class – Example 2: SSRI	<7	24 (0.3%)		

663 **Table 4.** Continued.

---

22	Avoid $\geq 2+$ drugs from the same pharmacological class – Example 3: PPI	<7	40 (0.4%)
----	--	----	-----------

---

664 <sup>1</sup> Drugs of which judgment of PIP was dependant on prescribed dose or duration, prevalence of PIPs was reported separately for patients having  
665 complete information on dose or duration.

666 **Abbreviations:** COPD: Chronic obstructive pulmonary disease; SSRI: Selective serotonin reuptake inhibitors; eGFR: Estimated glomerular filtration  
667 rate; ADR: Adverse drug reaction; ADH: antidiuretic hormone; NSAID: Non-steroidal anti-inflammatory drugs; PPI: Proton pump inhibitors; CCB:  
668 calcium-channel blockers; BB: Beta blocker; BZD: Benzodiazepines; UTI: Urinary tract infections; SU: Sulfonylureas.

669

670

671

672

673

674

675